Mabwell (Shanghai) Bioscience Co Ltd. Stock Analysis 688062.SS

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical company, which engages in the research and development, manufacturing, and commercialization of therapeutic biological products. The company is headquartered in Shanghai, Shanghai and currently employs 1,325 full-time employees. The company went IPO on 2022-01-18. The Company’s business includes the research, development, transfer, technical services for and production and sales of new pharmaceutical and chemical technologies and new pharmaceutical products. The firm owns one Core Product 9MW2821 (bulumtatug fuvedotin) (“BFv”), a Nectin cell adhesion molecule 4 (“Nectin-4”) targeting antibody-drug conjugate (“ADC”) (the “Nectin-4 targeting ADC”). The firm sells pharmaceutical products to third-party contract sales organizations. Its out-licensing arrangements business includes Licenses of intellectual property rights, research and development services, milestone payments and royalties.